Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 2 2Phase 1 1

Status

Active not recruiting 4Recruiting 2

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Papillomavirus Infections 2Neoplasms 1Human Papillomavirus-Related Cervical Carcinoma 1Human Papillomavirus-Related Carcinoma 1Hematologic Neoplasms 1

Interventions

Specimen Handling 655pembrolizumab 608Magnetic Resonance Spectroscopy 561Carboplatin 449Cisplatin 398Cyclophosphamide 396Biopsy 380Nivolumab 325Paclitaxel 323Gemcitabine 317Radiotherapy 298Bevacizumab 248Dexamethasone 223fludarabine 215Docetaxel 202durvalumab 195Oxaliplatin 189venetoclax 186atezolizumab 183Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 170Radiation 168Doxorubicin 166Radiosurgery 161Ipilimumab 147Etoposide 142Leucovorin 140Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Human Papillomavirus Recombinant Vaccine nonavalent × 90 days × Clear all
NCT03036930 2026-05-29

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

National Cancer Institute (NCI)

Phase 2 Active not recruiting
51 enrolled 10 charts

Papillomavirus Infections

NCT05237947 2026-05-28

PRISMA

National Cancer Institute (NCI)

Phase 4 Active not recruiting
5,000 enrolled
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

NCT03023631 2026-05-20

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 4 Active not recruiting
48 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT05985681 2026-05-13

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

National Cancer Institute (NCI)

Phase 1 Recruiting
18 enrolled

Human Papillomavirus-Related Carcinoma

NCT04206813 2026-04-29

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

Boston Medical Center

Phase 4 Active not recruiting
352 enrolled

Papillomavirus Infections

NCT06658405 2026-03-18

HPV2

Centre Oscar Lambret

Phase 2 Recruiting
85 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡